Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19

The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04499313

Enrollment

Registered

2020-08-05

Start date

2020-08-02

Completion date

2020-11-30

Last updated

2020-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Covid19

Keywords

COVID 19, Dexamethasone, Methylprednisolone, ARDS

Brief summary

A randomized clinical trial designed and intended to evaluate the efficacy of Dexamethasone and Methylprednisolone as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by coronavirus disease 19 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.

Interventions

DRUGDexamethasone

Injectable solution

DRUGMethylprednisolone

Injectable solution

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

• Moderate to severe COVID-19 requires hospitalization. SARS-CoV-2 infection will be confirmed by RT PCR / CT Chest in every case.

Exclusion criteria

* Participants with uncontrolled clinical status who were hospitalized from the before. * Contraindication / possible drug interaction. * Participants who have any severe and/or uncontrolled medical conditions like, Severe ischemic heart disease, epilepsy, malignancy, Pulmonary/renal/hepatic disease, pregnancy, Corpulmonale, etc.

Design outcomes

Primary

Measure	Time frame	Description
Mortality rate (In hospital)	Following randomization 30 days.	—
Clinical improvement	Following randomization 30 days.	The number of participants with Clinical improvement determined by the improvement of individual presenting symptoms of the COVID19; changes in radiological and laboratory values.Patient admitted in general bed requiring High Dependency Unit (HDU), and an HDU patient requiring Ventilator or Intensive care support.

Secondary

Measure	Time frame	Description
Ventilator free days	Following randomization 30 days.	—
Changes in Oxygen level	Following randomization 30 days.	Oxygen saturation in the peripheral blood determined by pulse oximetry.

Countries

Bangladesh

Contacts

Primary ContactAbu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD

dr_mohiuddinchy@yahoo.com008801817711079

Backup ContactShubhashis Talukder, MBBS, DO

drshubhashis@gmail.com008801911882232

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026